哈哈！AiCuris公司生殖器疱疹新药提前完成II期临床 [复制链接]

顶啊

AiCuris今天宣布次演示基础与上一阶段的数据AIC316在荷兰阿姆斯特丹的抗病毒药物代表大会，从7 - 9 日 2010年十一月。 AIC316是一种新型的抗HSV药物临床试验，目前第2阶段。
AiCuris科学家和项目负责人亚历山大Birkmann博士将通过展示从感染的小鼠模型进行实验，第一期的预测表明，有效的AIC316药浓度数据将很容易功效数据一项关于AIC316药代动力学，药效学的关系概述实现了人类。口头报告将在全体会议上举行了“抗病毒抵抗”星期一11月8日定于2010年5日14点40小时，新罕布什尔州大酒店威尼斯人度假村，阿姆斯特丹。

“调查结果也清楚地证实，AIC316有每天服用一次，我们作为生殖器疱疹打算指示的先决条件考虑潜在的”霍尔格齐默尔曼博士说，首席科学官AiCuris。 AiCuris公司首席执行官教授埃尔加Rübsamen - Schaeff补充说：不重要的“传染病”生殖器和唇疱疹，可视为“因为他们通常是自限性，会有相应的药物来治疗他们，但我们知道，患者可能遭受巨大。身体和心理上，而满足的医疗需求仍然很高。因此，我们致力于做一个具有创新性和抗单纯疱疹性破毒品真正的差别。“

来源：AiCuris

AiCuris has completed a double-blind randomised placebo controlled dose-finding Phase-II trial to investigate different doses of a new antiviral drug in subjects with genital HSV Type 2 infection and is planning have first data in early 2011.


AiCuris said that the trial has been completed two months earlier than planned.

Indeed, in the later stages of the trial, enrollment had to be restricted as the number of subjects was higher than the number that was required to be enrolled according to the trial protocol.

AiCuris Clinical Development associate director Burkhard Timmler said that they were surprised by the interest in the trial and the number of requests for participation that they received from people infected with herpes simplex virus.

"In spite of available therapeutic options there seems to be a great demand for a new, well tolerated and efficacious drug for people suffering from genital herpes," Timmler said.

AiCuris CEO Rubsamen-Schaeff said that they hope that the results will allow us to determine the efficacious dose of AIC316 and confirm the potential for once daily oral dosing in genital herpes.


Share:        

我看了原帖英文， 不过还是抑制药， 不是根治药， 解决不了问题。  只是一天一次而已。  有什么用呢。  不能根治的药， 都没用